Evidence map›Paper›PMID 40828532›Full record

Observational studyJAMA network open2025

Risk Factors for Severe Pediatric Invasive Group A Streptococcal Disease.

Evelien B van Kempen, Adam J Tulling, Erik G J von Asmuth, Leontien B van der Aa, Else M Bijker, Merijn Bijlsma, Dorine M Borensztajn, Caroline L H Brackel, Brechje de Gier, Marlies A van Houten and 17 more

Abstract readObservational Study
In one paragraph

Observational study in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Observational
  2. Lysosomal permeabilization by Group AInfection and immunity · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Lysosomal permeabilization by Group AbioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Evelien B van KempenDepartment of Pediatrics, Juliana Children's Hospital, Haga Hospital, the Hague, the Netherlands.
Adam J TullingDepartment of Paediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Erik G J von AsmuthDepartment of Paediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Leontien B van der AaDepartment of Pediatrics, Zaans Medical Center, Zaandam, the Netherlands.
Else M BijkerDepartment of Pediatrics, Maastricht University Medical Centre, MosaKids Children's Hospital, Maastricht, the Netherlands.
Merijn BijlsmaDepartment of Pediatrics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Dorine M BorensztajnDepartment of Pediatrics, Noordwest Ziekenhuisgroep, Alkmaar and Den Helder, the Netherlands.
Caroline L H BrackelDepartment of Pediatrics, Tergooi Medical Center, Hilversum, the Netherlands.
Brechje de GierCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Marlies A van HoutenDepartment of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Netherlands.
Monique A M JacobsDepartment of Pediatrics, Slingeland Ziekenhuis, Doetinchem, the Netherlands.
Marianne KoenraadsDepartment of Pediatrics, Haaglanden Medisch Centrum, the Hague, the Netherlands.
Anjali I G KooterDepartment of Pediatrics, Alrijne Ziekenhuis, Leiderdorp, the Netherlands.
Ankie LebonDepartment of Pediatrics, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Jan W M van der LindenDepartment of Pediatrics, Bernhoven, Uden, the Netherlands.
Lonneke van Onzenoort-BokkenDepartment of Pediatrics Máxima Medisch Centrum Veldhoven, the Netherlands.
Rianne OostenbrinkDepartment of Paediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Joffrey van PrehnDepartment of Medical Microbiology and Infection Prevention, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Nina M van SorgeDepartment of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Kim StolDepartment of Pediatrics, Radboud University Medical Center, Amalia Children's hospital, Nijmegen, the Netherlands.
Gerdien A Tramper-StrandersDepartment of Pediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
Aline R VerhageDepartment of Pediatric Infectious Diseases & Immunology, Beatrix Children's Hospital University Medical Center Groningen, Groningen, the Netherlands.
Kirsten N G van de WeijerDepartment of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Netherlands.
Joanne G WildenbeestDepartment of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Navin P BoeddhaDepartment of Pediatrics, Maasstad Hospital, Rotterdam, the Netherlands.
Mirjam van VeenDepartment of Pediatrics, Juliana Children's Hospital, Haga Hospital, the Hague, the Netherlands.
Emilie P BuddinghDepartment of Paediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: An increase in pediatric cases of invasive group A streptococcus (iGAS) disease was noted in the Netherlands starting in early 2022. GAS disease can range from mild to life-threatening invasive infections. Clinical and public health decisions rely on timely and detailed reporting of clinical data. Objective: To determine risk factors associated with severe pediatric iGAS, defined as requiring admission to an intensive care unit and/or death, and to analyze pediatric iGAS incidence, presentations, and outcome between pre-COVID-19 pandemic (January 2015 to March 2020), COVID-19 pandemic (April 2020 to December 2021), and post-COVID-19 pandemic (January 2022 to June 2024) periods. Design, Setting, and Participants: This observational, retrospective and prospective cohort study in 20 hospitals (tertiary and nontertiary) in the Netherlands was conducted from January 2015 to June 2024, with real-time reporting of data on the study website since January 2022. Children aged 0 to 17 years with iGAS (positive culture or polymerase chain reaction test and/or clinical presentation) were included. Exposure: iGAS infection. Main Outcome and Measures: The primary outcome was risk factors for severe iGAS; secondary outcomes included iGAS incidence rate and clinical phenotypes prior, during, and after the COVID-19 pandemic. Risk factors for severity and mortality were analyzed using univariable and multivariable logistic regression analyses, and incidence rate ratios (IRRs) between pre-COVID-19 and postCOVID-19 pandemic periods were calculated using Poisson regression. Results: Of 617 children included, 351 (56.9%) were aged 0 to 4 years. For the 192 participants with detailed data collection, median (IQR) age was 4.2 (1.7-7.1) years and 91 (47.4%) were male. iGAS cases decreased during the COVID-19 pandemic and increased significantly in the post-COVID-19 period (IRR, 2.93; 95%, 2.46-3.49), as compared with the pre-COVID-19 pandemic period. By late 2023, the incidence of iGAS returned to pre-COVID-19 pandemic levels. Factors associated with increased risk of severe disease included a post-COVID-19 pandemic diagnosis (odds ratio [OR], 3.49; 95% CI, 2.31-6.26), pulmonary involvement (OR, 8.64; 95% CI, 5.50-13.55), streptococcal toxic shock syndrome (STSS; OR, 11.71; 95% CI, 4.39-31.18), and meningitis or encephalitis (OR, 4.38; 95% CI, 4.39-31.18). Clinical factors associated with increased risk of severe disease were reduced consciousness (OR, 7.61; 95% CI, 1.84-34.41), dyspnea (OR, 9.89; 95% CI, 3.04-32.14), abnormal auscultation (OR, 6.32; 95% CI, 2.18-18.32), and elevated C-reactive protein (OR, 6.32; 95% CI, 2.18-18.32), while estimated glomerular filtration rate was associated with a decreased risk (OR, 0.64; 95% CI, 0.49-0.84). Disease severity increased in post-COVID-19-pandemic cases, with higher mortality (13 of 294 cases [4.4%] vs 3 of 218 cases [1.4%]) and intensive care admission rates (113 of 294 cases [38.4%] vs 34 of 218 cases [15.6%]), as compared with pre-COVID-19 pandemic cases. Severity of pulmonary iGAS was similar in both periods. In the post-COVID-19 pandemic period, there was a significant increase in the incidence of pulmonary infections (IRR, 5.04; 95% CI, 3.27-7.97) , STSS (IRR, 10.30; 95% CI, 3.88-35.60), meningitis or encephalitis (IRR, 12.30; 95% CI, 4.14-52.70), and necrotizing fasciitis (IRR, 26.10; 95% CI, 5.14-475.00). Conclusions and Relevance: In this cohort study, risk factors for a complicated course of iGAS in children included pulmonary or central nervous system involvement, STSS, reduced consciousness or pulmonary clinical signs, elevated CRP, and decreased eGFR. Awareness of these risk factors is important to improve timely recognition of at-risk cases and improve clinical outcomes.

Indexed as

COVID-19Streptococcal InfectionsStreptococcus pyogenesAdolescentChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornMaleNetherlandsPandemicsProspective StudiesRetrospective Studies

Identifiers

PMID40828532
PMCPMC12365701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.